Yan Ningning, Huang Siyuan, Li Linlin, Guo Qianqian, Geng Di, Zhang Huixian, Guo Sanxing, Li Xingya
Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Front Pharmacol. 2022 Sep 9;13:898623. doi: 10.3389/fphar.2022.898623. eCollection 2022.
Immune checkpoint inhibitors (ICIs) have greatly transformed the treatment and improved the prognosis for patients with non-small cell lung cancer (NSCLC) without driver gene alterations. However, the effects of ICI combination therapy in ROS1 fusion-positive NSCLC remains unclear. Herein, we present a case with ROS1 fusion-positive NSCLC treated with ICI plus chemotherapy. The patient achieved a continuous partial response (PR) to ICI plus chemotherapy and a more than 35 months progression free survival. This case demonstrates that ICI plus chemotherapy is a promising option for patients with ROS1 fusion-positive NSCLC.
免疫检查点抑制剂（ICI）极大地改变了无驱动基因改变的非小细胞肺癌（NSCLC）患者的治疗方式并改善了其预后。然而，ICI联合疗法在ROS1融合阳性NSCLC中的疗效仍不明确。在此，我们报告1例接受ICI联合化疗治疗的ROS1融合阳性NSCLC患者。该患者对ICI联合化疗持续产生部分缓解（PR），无进展生存期超过35个月。该病例表明，ICI联合化疗是ROS1融合阳性NSCLC患者的一种有前景的选择。
Zotero 插件